vs
Side-by-side financial comparison of BOS BETTER ONLINE SOLUTIONS LTD (BOSC) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
BOS BETTER ONLINE SOLUTIONS LTD is the larger business by last-quarter revenue ($26.6M vs $16.1M, roughly 1.7× Journey Medical Corp). BOS BETTER ONLINE SOLUTIONS LTD runs the higher net margin — 8.0% vs -7.8%, a 15.7% gap on every dollar of revenue. On growth, BOS BETTER ONLINE SOLUTIONS LTD posted the faster year-over-year revenue change (34.6% vs 27.3%).
B.O.S. Better Online Solutions Ltd. is a publicly traded company, headquartered in Israel, that provides RFID and supply chain solutions. Its shares are traded on the NASDAQ Capital Market.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
BOSC vs DERM — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.6M | $16.1M |
| Net Profit | $2.1M | $-1.2M |
| Gross Margin | 23.4% | — |
| Operating Margin | 6.8% | -2.8% |
| Net Margin | 8.0% | -7.8% |
| Revenue YoY | 34.6% | 27.3% |
| Net Profit YoY | 70.2% | -182.0% |
| EPS (diluted) | $0.33 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $16.1M | ||
| Q3 25 | — | $17.0M | ||
| Q2 25 | $26.6M | $15.0M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | $19.7M | $14.9M | ||
| Q1 24 | — | $13.0M |
| Q4 25 | — | $-1.2M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | $2.1M | $-3.8M | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $1.2M | $-3.4M | ||
| Q1 24 | — | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 23.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | 24.1% | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | — | -2.8% | ||
| Q3 25 | — | -9.0% | ||
| Q2 25 | 6.8% | -19.2% | ||
| Q1 25 | — | -25.3% | ||
| Q4 24 | — | 17.7% | ||
| Q3 24 | — | -19.8% | ||
| Q2 24 | 7.6% | -19.7% | ||
| Q1 24 | — | -77.4% |
| Q4 25 | — | -7.8% | ||
| Q3 25 | — | -13.6% | ||
| Q2 25 | 8.0% | -25.3% | ||
| Q1 25 | — | -31.0% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | — | -16.3% | ||
| Q2 24 | 6.3% | -22.6% | ||
| Q1 24 | — | -80.1% |
| Q4 25 | — | $-0.04 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | $0.33 | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $-0.12 | ||
| Q2 24 | $0.21 | $-0.17 | ||
| Q1 24 | — | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.2M | $24.1M |
| Total DebtLower is stronger | — | $25.3M |
| Stockholders' EquityBook value | $24.2M | $31.9M |
| Total Assets | $38.4M | $94.6M |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.1M | ||
| Q3 25 | — | $24.9M | ||
| Q2 25 | $5.2M | $20.3M | ||
| Q1 25 | — | $21.1M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | — | $22.5M | ||
| Q2 24 | $2.4M | $23.9M | ||
| Q1 24 | — | $24.1M |
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $25.2M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $19.8M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | — | $31.9M | ||
| Q3 25 | — | $25.9M | ||
| Q2 25 | $24.2M | $19.2M | ||
| Q1 25 | — | $21.5M | ||
| Q4 24 | — | $20.1M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | $20.1M | $11.3M | ||
| Q1 24 | — | $13.0M |
| Q4 25 | — | $94.6M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | $38.4M | $81.2M | ||
| Q1 25 | — | $85.0M | ||
| Q4 24 | — | $80.2M | ||
| Q3 24 | — | $64.0M | ||
| Q2 24 | $31.8M | $65.2M | ||
| Q1 24 | — | $66.6M |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 1.30× | ||
| Q1 25 | — | 1.16× | ||
| Q4 24 | — | 1.24× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.5M | $-6.3M |
| Free Cash FlowOCF − Capex | $1.2M | — |
| FCF MarginFCF / Revenue | 4.5% | — |
| Capex IntensityCapex / Revenue | 1.0% | — |
| Cash ConversionOCF / Net Profit | 0.69× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | $1.5M | $-942.0K | ||
| Q1 25 | — | $-2.8M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | $320.0K | $-5.2M | ||
| Q1 24 | — | $-5.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $75.0K | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.26× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOSC
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
